- The United States Biomedical Advanced Research and Development Authority (BARDA) has announced Vaxxas will receive US$2 million (AU$3.2 million) as a Concept Stage Winner in its multi-stage $50 ...

Vaxxas Pty Ltd today announced the appointment of global biopharmaceutical executive Mr David Peacock as Chief Executive ...

Seasoned global pharmaceutical executive, Mr Brent MacGregor, joins Vaxxas Board to accelerate self-administered HD-MAP vaccines for global use; SPRIM Global Investment’s Co-Founder and Managing ...

The MarketWatch News Department was not involved in the creation of this content. -- Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via "patch" technology and utilizes ...

CEPI has approved the advancement of the vaccine program following promising proof-of-concept results generated by Vaxxas in preclinical models, showing excellent thermostability and effective ...

Panther is inviting pharmaceutical and biotechnology partners to co-develop higher-efficacy, lower-toxicity, shelf-stable therapies using its MAP platform. We believe rethinking how treatments are ...

Vaxxas has appointed former Merck Global Vaccines president David Peacock as chief executive officer (CEO), marking a step in ...

Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via “patch” technology and utilizes Micron’s first-in-class dissolvable microarray technology Research builds on Emory’s ...